

# Niloufer Khan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6526141/publications.pdf>

Version: 2024-02-01

26  
papers

1,919  
citations

759233

12  
h-index

752698

20  
g-index

26  
all docs

26  
docs citations

26  
times ranked

3659  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. <i>Blood Cancer Journal</i> , 2022, 12, 29.   | 6.2  | 1         |
| 2  | Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Cutaneous T Cell Lymphoma. <i>Journal of Palliative Medicine</i> , 2022, 25, 958-963.   | 1.1  | 1         |
| 3  | Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study. <i>Blood</i> , 2021, 137, 1527-1537.  | 1.4  | 42        |
| 4  | The experience of financial toxicity among advanced melanoma patients treated with immunotherapy. <i>Journal of Psychosocial Oncology</i> , 2021, 39, 285-293.   | 1.2  | 18        |
| 5  | Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2257-2265.   | 1.6  | 32        |
| 6  | Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 2529-2529.  | 1.4  | 0         |
| 7  | Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL). <i>Blood</i> , 2021, 138, 2447-2447.                                  | 1.4  | 1         |
| 8  | TP53 Mutations Identify High-Risk Peripheral T-Cell Lymphoma Patients Treated with CHOP-Based Chemotherapy. <i>Blood</i> , 2021, 138, 1367-1367.   | 1.4  | 2         |
| 9  | Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience. <i>Blood</i> , 2021, 138, 2513-2513.  | 1.4  | 0         |
| 10 | Favorable Outcomes of Patients with Limited-Stage Ocular Adnexal DLBCL Treated in the Rituximab Era: Long-Term Follow-up of a Single Center Experience. <i>Blood</i> , 2021, 138, 4578-4578.   | 1.4  | 0         |
| 11 | How we treat mycosis fungoides and S azary syndrome. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19, 573-581.  | 0.3  | 0         |
| 12 | Patient preferences for first-line treatment of classical Hodgkin lymphoma: a US survey and discrete choice experiment. <i>Leukemia and Lymphoma</i> , 2020, 61, 2630-2637.  | 1.3  | 8         |
| 13 | Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors. , 2020, 8, e000260.  |      | 33        |
| 14 | Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2020, 382, 822-834.  | 27.0 | 435       |
| 15 | Single agents vs combination chemotherapy in relapsed and refractory peripheral T cell lymphoma: Results from the comprehensive oncology measures for peripheral T cell lymphoma treatment (COMPLETE) registry. <i>American Journal of Hematology</i> , 2019, 94, 641-649. | 4.1  | 25        |
| 16 | Immunotherapy in mycosis fungoides: opening night or dress rehearsal?. <i>Leukemia and Lymphoma</i> , 2019, 60, 864-866.   | 1.3  | 0         |
| 17 | A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 4033-4033.   | 1.4  | 2         |
| 18 | Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2018, 360, k793.  | 2.3  | 438       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Peripheral T-cell lymphoma “ are we making progress?. Best Practice and Research in Clinical Haematology, 2018, 31, 306-314.                                     | 1.7  | 8         |
| 20 | Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leukemia and Lymphoma, 2017, 58, 2127-2133.                               | 1.3  | 20        |
| 21 | Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?. Current Hematologic Malignancy Reports, 2017, 12, 227-233.                              | 2.3  | 8         |
| 22 | Psychological morbidities in adolescent and young adult blood cancer patients during curative intent therapy and early survivorship. Cancer, 2016, 122, 954-961. | 4.1  | 60        |
| 23 | <i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. New England Journal of Medicine, 2016, 375, 2023-2036.                       | 27.0 | 663       |
| 24 | Plaque Brachytherapy for Uveal Melanoma: A Vision Prognostication Model. International Journal of Radiation Oncology Biology Physics, 2012, 84, e285-e290.       | 0.8  | 18        |
| 25 | Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents. OncoTargets and Therapy, 2011, 4, 137.                  | 2.0  | 46        |
| 26 | The Evolving Role of Radiation Therapy in the Management of Malignant Melanoma. International Journal of Radiation Oncology Biology Physics, 2011, 80, 645-654.  | 0.8  | 58        |